Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study

Dufour, Jean-François; Hoppe, Hanno; Heim, Markus H; Helbling, Beat; Maurhofer, Olivier; Szucs-Farkas, Zsolt; Kickuth, Ralph; Borner, Markus; Candinas, Daniel; Saar, Bettina (2010). Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist, 15(11), pp. 1198-204. Miamisburg, Ohio: AlphaMed Press 10.1634/theoncologist.2010-0180

Full text not available from this repository. (Request a copy)

It is unknown whether sorafenib can be combined with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma. This study assesses the safety and tolerability of a continuous regimen of sorafenib combined with TACE.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Service Sector > Institute of Clinical Pharmacology and Visceral Research [discontinued] 04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Institute of Diagnostic, Interventional and Paediatric Radiology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery
UniBE Contributor:	Dufour, Jean-François, Hoppe, Hanno, Szücs Farkas, Zsolt, Kickuth, Ralph, Borner, Markus, Candinas, Daniel, Saar, Bettina
ISSN:	1083-7159
Publisher:	AlphaMed Press
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:09
Last Modified:	05 Dec 2022 14:00
Publisher DOI:	10.1634/theoncologist.2010-0180
PubMed ID:	21036880
Web of Science ID:	000284758000009
URI:	https://boris.unibe.ch/id/eprint/832 (FactScience: 200979)